For patients with wild-type KRAS , median progression-free survival was 26 months for dacomitinib ( 95 % CI 19-29 ) and erlotinib ( 95 % CI 19-30 ; stratified HR 1022 , 95 % CI 0834-1253 , one-sided p = 0587 ) .